铂类药物与肌肉不良反应的关联研究

We collected adverse event reports involving platinum-based drug therapy and muscle-related adverse reactions submitted to the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2023 and to the World Health Organization's global pharmacovigilance database (VigiBase) from 1968 to 2023. We used the Reporting Odds Ratio (ROR) method for disproportional analysis to evaluate the association between platinum-based drugs and muscle adverse reactions, and supplemented this analysis with local patient data, cell, and animal experiments. Finally, we combined transcriptomic data from the Cancer Genome Atlas (TCGA) pan-cancer dataset and platinum-treated mouse muscle tissue transcriptomic data to investigate the related biological mechanisms.